Navigation Links
TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
Date:8/19/2007

TAIPEI, Taiwan, Aug. 10 /Xinhua-PRNewswire/ -- TaiGen Biotechnology Inc. announces the successful completion of patient recruitment for the global double-blind Phase II clinical trial of Nemonoxacin (TG-873870) for the treatment of adult community-acquired pneumonia (CAP). A total of 265 patients have been admitted to the trial. Completion of the trial data analysis is expected in the last quarter of 2007. In this trial, the effect of Nemonoxacin in comparison with levofloxacin, the leading quinolone on the market, is evaluated with both clinical and bacteriological success rates in treating adult patients with CAP.

"We are pleased with the efficient manner in which the 18 clinical centers have enrolled patients in the phase II study," said Dr. Ming Chu Hsu, Chairman and CEO of TaiGen. "Completing enrollment in this study shall keep us on track of our projected development timeline for this highly promising antibacterial for the treatments of resistant infection."

About TaiGen Biotechnology Co., LTD

TaiGen Biotechnology (http://www.taigenbiotech.com ) is a leading pharmaceutical company based in Taiwan and has a wholly-owned subsidiary in Beijing, China. The company is developing novel therapeutics to treat infectious diseases, diabetic complications and cancer for the worldwide market. TaiGen has a full capacity in new drug R&D and clinical development in China, Taiwan, US and other countries. Nemonoxacin, an once-a-day oral and IV antibacterial active against gram-positive and -negative pathogens and MRSA, will soon to enroll diabetic foot infection patients in a double-blind phase 2 trial. The company has first-in-class phase 1-ready drug candidates for treating critical limb ischemia and retinopathy/age-related macular degeneracy, and advanced preclinical candidates for chronic Hepatitis C virus infection and cancer.

Contact Information:

Stephen Ip, Ph.D.

SVP Global Business Development

Tel: +886-2-2790-1861

Fax: +8862-2790-9962

Email: sip@taigenbiotech.com

Add: 7F, 138 Shin Ming Rd., Neihu Dist., Taipei, Taiwan 11470, R.O.C.


'/>"/>
SOURCE TaiGen Biotechnology Co., LTD

Copyright©2007 PR Newswire.

Related medicine technology :

1. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
2. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
3. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
4. Beike Biotechnology Study Suggests Adult Stem Cells Show Promise for Peripheral Vascular Disease
5. Prana Biotechnology Presents New Key Findings on PBT2
6. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ASCO Annual Meeting
7. Generex Biotechnology Vaccine Strategy Presented at International Conference in London
8. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at AUA Annual Meeting
9. Cougar Biotechnology Presents Positive CB7630 Clinical Data at AACR Annual Meeting Late-Breaking Clinical Trials Session
10. Pegasys Study Authors Conclude that Patients Successfully Treated for Hepatitis C Can be Considered Cured
11. Ace Biosciences, Ace393, the Worlds First Commercial Vaccine for Travellers Diarrhoea Caused by Campylobacter Successfully Completes Phase I Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)...   Hudes Laser Aesthetica announced their ... Astanza Trinity laser and Astanza Liberty IPL technologies. ... removal, IPL hair removal, pigmented and vascular lesion ... Aesthetica is setting high standards for aesthetic clinics ... to deliver effective, long-lasting results. "Hudes ...
(Date:12/9/2016)... Fla. , Dec. 9, 2016  Harmar Mobility, LLC announced ... and a member of the Board of Directors. Photo ... ... Mr. Dawson,s ... development of organizations across a variety of industries. He brings to ...
(Date:12/9/2016)... DUBLIN , Dec 9, 2016 Research ... Vaccines Market 2016-2020" report to their offering. ... The global travel vaccines market ... The report covers the present scenario and the growth ... the market size, the report considers the revenue generated from the ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... December 08, 2016 , ... Premier Fitness Camp (PFC) ... , the ultimate weight loss and wellness program, at their world headquarters of Omni ... provide immediate and long-term results to anyone seeking weight loss, personal development, a healthy ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... development continuity to its innovative Unified Instance Manager architecture, meeting the needs ... this new version optimizes the unattended auto-dialing system without agents, Presence Robodialer, ...
(Date:12/8/2016)... ... December 08, 2016 , ... STATEN ISLAND, N.Y., Nov. ... adherence to the highest standards of trauma, maternity, cancer and chronic obstructive pulmonary ... and CEO, Dr. Daniel Messina. , Among the recognitions, the American College of ...
(Date:12/8/2016)... ... December 08, 2016 , ... California Senate Bill (SB) 863, ... workers’ compensation claim in 2013 and 2014, according to CompScope™ Medical Benchmarks for ... . , According to the study, medical payments per claim in California decreased 4 ...
(Date:12/8/2016)... ... December 08, 2016 , ... Healthcare is ... Dr. Botelho advocates for the mass media launching of story movements to highlight ... to share their unfortunate experiences; such a movement can generate the network power ...
Breaking Medicine News(10 mins):